

---

## Press Release

Press release of MaimoniDex RA Ltd. and Bioceros BV

### **Bioceros announces license option agreement with MaimoniDex RA for antibodies to be used for treatment of rheumatoid arthritis.**

**Utrecht, The Netherlands – January 7, 2008**

Biotechnology company Bioceros BV and antibody company Maimonidex RA Ltd. announce today they will start a collaboration on the development of a monoclonal antibody specific for CD44vRA, a splice variant of the adhesion molecule CD44, involved in the inflammatory process underlying Rheumatoid Arthritis (RA). Bioceros will be granted an option to a world-wide exclusive license on the intellectual property and technology owned by MaimoniDex.

MaimoniDex is an Israeli biotech company focused on discovering disease-specific targets for a variety of major diseases. MaimoniDex's core business is the treatment of RA with disease specific anti-CD44vRA monoclonal antibodies. Treatment of CD44vRA expressing synovial cells with these antibodies results in apoptosis of the activated synovial cells. CD44vRA is not expressed on normal tissues of the same patients and therefore this approach represents the first therapy specifically targeting RA at the site of the harmful inflammation.

In addition to its product portfolio, Bioceros offers services to customers on generation of high protein producing mammalian (CHO based) cell lines and process development. Bioceros' Chief Executive Officer, Bram Bout, said: "This deal is in line with our strategy to expand our product portfolio with high potential monoclonal antibodies from top-experts in the field and which we can leverage through our technology platform".

"Working with Bioceros, with an excellent track record of successful partnerships, will enable the production of a commercially viable humanized monoclonal antibody for treating RA. We are confident that their experience and professional abilities can deliver a superior product in a timely manner. We are pleased to collaborate with Bioceros in the development of the first specific drug for RA", said Dr. Itshak Golan, President and Chief Executive Officer of MaimoniDex.

Financial terms of the collaboration were not disclosed.

For further information, visit [www.bioceros.com](http://www.bioceros.com) or contact:

**MaimoniDex RA Ltd.:**

Dr. Itshak Golan (CEO)  
23 Gainsborough Garden  
Golders Green, London NW11 9BJ  
United Kingdom  
tel. +44 77 9123 5930  
[i.golan@imperial.ac.uk](mailto:i.golan@imperial.ac.uk)

**Bioceros BV:**

Remco M. Brandt, M.Sc. (COO)  
Yalelaan 46  
3584 CM Utrecht  
The Netherlands  
tel. +31 30-253 7910  
[r.brandt@bioceros.com](mailto:r.brandt@bioceros.com)